FDA
-
-
-
-
-
-
-
NeOnc Technologies sets phase 2 dose for brain cancer drug NEO212
-
-
-
-
-
-
-
NeOnc Technologies Reports Updated Clinical Results
-
-
-
-
-
-
-
His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment
-
-
-
-
-
-
-
NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
-
-
-
-
-
-
-
NeOnc Technologies acquires AI and quantum modeling IP for $3.5 million
-
-
-
-
-
-
-
NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment
-
-
-
-
-
-
-
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
-
322,239 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

